Meeting
2012 Genitourinary Cancers Symposium
Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Samuel Craig Brondfield
University of California, San Francisco, San Francisco, CA
Samuel Craig Brondfield , Vivian K. Weinberg , Kathryn M. Koepfgen , Arturo Molina , Charles J. Ryan , Eric Jay Small , Andrea Lynne Harzstark
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session C: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 30, 2012 (suppl 5; abstr 222)
DOI
10.1200/jco.2012.30.5_suppl.222
Abstract #
222
Poster Bd #
C23
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Comparative analysis of sarcopenia induced by long-term abiraterone (A) versus enzalutamide (E) therapy in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Mahdi Farzad Naimi
Poster
2017 Gastrointestinal Cancers Symposium
Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma.
First Author: Go Ninomiya
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment (Tx) sequences and time to discontinuation (rwTTD) in the first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) setting.
First Author: Emily Nash Smyth
Poster
2024 ASCO Genitourinary Cancers Symposium
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Dana E. Rathkopf